Canaccord Genuity set a $22.00 target price on Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) in a report released on Tuesday morning. The brokerage currently has a buy rating on the stock.

Other equities research analysts also recently issued research reports about the stock. BidaskClub downgraded shares of Aquinox Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, July 28th. Zacks Investment Research downgraded shares of Aquinox Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, May 9th. ValuEngine raised shares of Aquinox Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, June 2nd. Finally, Cantor Fitzgerald set a $28.00 price objective on shares of Aquinox Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday, May 9th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $22.50.

Aquinox Pharmaceuticals (NASDAQ AQXP) traded down 4.523% during trading on Tuesday, reaching $13.615. 28,226 shares of the company were exchanged. Aquinox Pharmaceuticals has a 52-week low of $8.36 and a 52-week high of $19.97. The firm’s market cap is $318.90 million. The firm has a 50-day moving average of $14.56 and a 200-day moving average of $15.60.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.59). On average, equities analysts forecast that Aquinox Pharmaceuticals will post ($2.18) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Given a $22.00 Price Target by Canaccord Genuity Analysts” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.dailypolitical.com/2017/08/09/aquinox-pharmaceuticals-inc-nasdaqaqxp-given-a-22-00-price-target-by-canaccord-genuity-analysts.html.

In other news, insider David Main sold 15,625 shares of the stock in a transaction on Monday, June 5th. The shares were sold at an average price of $13.26, for a total transaction of $207,187.50. Following the completion of the sale, the insider now owns 77,530 shares of the company’s stock, valued at $1,028,047.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.70% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Archon Partners LLC boosted its position in shares of Aquinox Pharmaceuticals by 44.0% in the second quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock valued at $253,000 after buying an additional 5,500 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Aquinox Pharmaceuticals by 16.5% in the second quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock valued at $327,000 after buying an additional 3,299 shares during the last quarter. Alps Advisors Inc. boosted its position in shares of Aquinox Pharmaceuticals by 4.7% in the second quarter. Alps Advisors Inc. now owns 21,090 shares of the company’s stock valued at $297,000 after buying an additional 939 shares during the last quarter. Investment Centers of America Inc. acquired a new position in shares of Aquinox Pharmaceuticals during the first quarter valued at approximately $172,000. Finally, Geode Capital Management LLC boosted its position in shares of Aquinox Pharmaceuticals by 10.0% in the first quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock valued at $2,028,000 after buying an additional 11,035 shares during the last quarter. Institutional investors and hedge funds own 98.32% of the company’s stock.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.